ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...

“Now it is approved for lung cancer, gynecological cancers, biliary tract cancers – any type of cancer which expresses a target in the cancer cells called HER2-positive.” If your doctor has ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate that could challenge rival drugs from AstraZeneca/Daiichi Sankyo and Roche.

The report delves into key HER2+ Non Small Cell Lung Cancer statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging HER2+ Non Small ...

Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer. All patients with breast cancer who may be candidates for antibody-drug ...

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer. On Jan. 27, the Food and Drug Administration (FDA) ...

Tucatinib inhibits the tyrosine kinase enzyme of the HER-2 gene. Mutations of tyrosine kinase in the HER-2 gene lead to ...

Evorpacept shows promising tumor response in HER2-positive cancers, with durable efficacy and favorable safety results from ASPEN-06 trial. ALX Oncology announced promising results from the ASPEN ...

Factors influencing this expansion include: The growing prevalence of breast cancer plays ... Kadcyla is a targeted treatment that integrates the HER2-targeting antibody trastuzumab with the ...

The prevalence of MTAP-deletion is estimated to ... patients and in more than 40 countries for certain patients with pre-treated HR+/HER2- metastatic breast cancer. In addition to the Phase ...